

Prescribing Clinical Network

Policy Statement	Alimemazine tartrate (trimeprazine tartrate) for the treatment of sleep disorders in children & adolescents (unlicensed indication)
Policy No:	PCN 286 - 2017
Date of Issue	December - 2017
Review Date:	December - 2020 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
<p>Recommendations: The PCN does not recommend Alimemazine (trimeprazine) for the unlicensed treatment of sleep disorders in children and adolescents.</p> <p>Alimemazine (trimeprazine) will be considered BLACK, for new patients, on the traffic light system</p> <p>Patients whose treatment with Alimemazine was initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant within 12 months, but should be able to continue treatment until, the patient and their NHS consultant consider it appropriate to stop.</p>	
<p>Key Considerations:</p> <ul style="list-style-type: none"> • Limited objective evidence available to demonstrate any benefit for patients. • Not a cost effective use of NHS resources given the significant list price increase. • Safety concerns were noted by PCN members with regards first generation H1 antihistamines. 	
Date taken to Prescribing Clinical Network	6 th December 2017
Agreed by PCN members	18 th December 2017

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG